Human Pathology
Volume 41, Issue 9 , Pages 1210-1219, September 2010

S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy

  • Mary Levy, DO

      Affiliations

    • Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    • ,
  • Fan Lin, MD, PhD

      Affiliations

    • Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA 17821, USA
    • ,
  • Haodong Xu, MD, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    • ,
  • Deepti Dhall, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    • ,
  • Betsy O. Spaulding, BS

      Affiliations

    • Dako North America, Carpinteria, CA 93013, USA
    • ,
  • Hanlin L. Wang, MD, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    • Corresponding Author InformationCorresponding author.

Received 12 December 2009; received in revised form 21 January 2010; accepted 22 January 2010. published online 12 April 2010.

Summary 

Histopathologic distinction between benign and malignant bile duct epithelial lesions on endoscopic biopsies can be extremely challenging because of limited material, crush artifact, and compounding inflammatory and/or reactive changes particularly after stent placement. In this study, a total of 72 endoscopic bile duct biopsies, including 40 adenocarcinomas and 32 benign cases, were immunohistochemically examined for the expression of S100P, von Hippel-Lindau gene product (pVHL), and IMP3 to evaluate their diagnostic value. The results showed that 36 adenocarcinomas (90%) exhibited strong nuclear and cytoplasmic staining for S100P, of which 30 (83.3%) showed diffuse immunoreactivity. Intermediate to strong cytoplasmic staining for IMP3 was demonstrated in 31 tumors (77.5%) (15 diffuse, 16 focal). Completely negative staining for pVHL was observed in 37 adenocarcinomas. In the remaining 3 tumors, focal (1) or diffuse (2) membranous and cytoplasmic pVHL immunoreactivity was detected. Twenty-eight tumors (70%) showed a S100P+/IMP3+/pVHL− staining pattern, 6 (15%) with a S100P+/IMP3−/pVHL− pattern, and 2 (5%) with a S100P−/IMP3+/pVHL− pattern. All 32 benign biopsies were completely negative for IMP3 with the exception of 2 cases with focal dysplasia where focal immunoreactivity was observed. Thirty benign biopsies (93.8%) were positive for pVHL with a diffuse staining pattern observed in 28 cases (93.3%). Eight benign biopsies (25%) showed focal S100P positivity. Twenty-two benign biopsies (68.8%) displayed a S100P−/IMP3−/pVHL+ staining pattern. In conclusion, an immunohistochemical panel consisting of S100P, pVHL, and IMP3 can be helpful in distinguishing adenocarcinoma from reactive epithelial changes on challenging bile duct biopsies. The findings of focal S100P and/or IMP3 expression with reciprocal loss of pVHL immunoreactivity in a few benign biopsies suggest a use of these markers in the detection of early epithelial dysplasia that may be beyond histologic recognition.

Keywords: Bile duct, Adenocarcinoma, Biopsy, S100P, pVHL, IMP3

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Presented in an abstract form at the 97th annual meeting of the United States and Canadian Academy of Pathology, Boston, MA, March 7-13, 2009.

PII: S0046-8177(10)00054-7

doi:10.1016/j.humpath.2010.01.014

Human Pathology
Volume 41, Issue 9 , Pages 1210-1219, September 2010

Article Tools

* Image Usage & Resolution